Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month High - What's Next?

Key Points

• Supernus Pharmaceuticals shares reached a new 52-week high of $45.01, experiencing significant trading volume of 1,047,668 shares.
• Analyst ratings have shown a positive shift, with Cantor Fitzgerald raising the target price to $46.00 and upgrades from Zacks Research to a "hold" rating, contributing to an average rating of "Moderate Buy" with a consensus target price of $41.00.
• Insider transactions have occurred, with significant sales including CEO Jack A. Khattar offloading 140,000 shares valued at approximately $5.88 million, indicating notable insider movement within the company.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as $45.01 and last traded at $44.92, with a volume of 1047668 shares. The stock had previously closed at $43.32.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald raised their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $41.00.

Supernus Pharmaceuticals Stock Performance

The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of 38.90 and a beta of 0.74. The company has a 50 day moving average of $35.41 and a 200 day moving average of $33.65.

Insider Buying and Selling

In other news, Director Frederick M. Hudson sold 7,457 shares of the company's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director directly owned 46,307 shares of the company's stock, valued at approximately $1,956,933.82. This represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jack A. Khattar sold 140,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer directly owned 1,030,183 shares of the company's stock, valued at approximately $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,826 shares of company stock valued at $6,424,773 in the last three months. 8.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Ashford Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 1.4% in the 2nd quarter. Ashford Capital Management Inc. now owns 574,372 shares of the specialty pharmaceutical company's stock valued at $18,104,000 after purchasing an additional 7,816 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of Supernus Pharmaceuticals by 0.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 220,304 shares of the specialty pharmaceutical company's stock valued at $6,944,000 after purchasing an additional 573 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Supernus Pharmaceuticals by 5.7% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 61,936 shares of the specialty pharmaceutical company's stock valued at $1,954,000 after purchasing an additional 3,336 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Supernus Pharmaceuticals by 255.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,245 shares of the specialty pharmaceutical company's stock valued at $134,000 after purchasing an additional 3,051 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at about $248,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.